The clinical trial to evaluate the efficacy of [11C]K-2 in epilepsy patients
- Conditions
- refractory epilepsy patients
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 8
1.refractory epilepsy patients(mesial temporal lobe epilepsy)
2.patinets for anterior temporal lobectomy(ATL)
3.patients who are without cerebral surgery on the same side of ATL
4.patients who are 20 years or older
5.patients who can consent to this study by oneself
1.patients who have significant abnormalities insides the brains
2.patients who have experienced the electric stimulation therapy
3.patients who undergo artificial dialysis
4.patients who have severe liver dysfunction
5.patients who have tatoo
6.claustrophobic patients
7.breast-feeding mothers, expecting mothers, females who desire to be a mother
8.patients who desire to bear a child within this study period
9.patients who take Fycompa
10.patients who underwent nuclear medicine examination within one-week before this registarion
11.patients who underwent other clinical trials using unapproved nuclear medicine examination within six month before this registarion
12.patients who underwent other clinical trials within 12 weeks before this registarion
13.patients whom study doctors consider unappropriate
Study & Design
- Study Type
- Interventional
- Study Design
- single assignment
- Primary Outcome Measures
Name Time Method - The correlation of the AMPA receptors densities examined by biochemical study and [11C]K-2 PET study
- Secondary Outcome Measures
Name Time Method Density of AMPA receptors and FDG-PET values Obtained from preoperative [11C]K-2 PET imaging
Cognitive function scores (IQ, MQ) Quantitative changes in cognitive function scores around surgery
Prescribed anti-epileptic drugs Quantitative changes in the number of types and the dose per day after surgery
Adverse events 7 days after PET scan The adverse events occurred in patients
Engel classification and ILAE classification Evaluation of postoperative epileptic seizures